Global S&T Development Trend Analysis Platform of Resources and Environment
Expert commentary: Oxford and AstraZeneca vaccine preliminary Phase III data | |
admin | |
2020-11-24 | |
发布年 | 2020 |
语种 | 英语 |
国家 | 澳大利亚 |
领域 | 地球科学 |
正文(英文) |
Their interim analysis shows the candidate is, on average, 70.4 per cent effective at preventing COVID-19 when combining data from two dosing regimens. CSIRO's expert Dr Rob Grenfell comments on the news. CSIRO Health and Biosecurity Director, Dr Rob GrenfellIt's very encouraging to see that in the higher efficacy dose regimen, a combination of a half dose followed by a full dose resulted in 90 per cent efficacy against the disease. At a time where demand for vaccines far outstrips supply, using one and a half doses rather than two means Australia's supply of the Oxford-AstraZeneca candidate will go much further. The interim data shows the vaccine reduced asymptomatic infections, and there were no severe cases or hospitalisations among those who received the vaccine. It's also important to see that the vaccine demonstrated a strong immune response in older people, a key high-risk group in this pandemic. CSIRO is pleased to have been able to play a role in the validation of this vaccine through pre-clinical testing at our Australian Centre for Disease Preparedness earlier this year. As part of CSIRO's preclinical trial of Oxford-AstraZeneca's candidate, our scientists evaluated the efficacy of one versus two doses as well as administration of the vaccine via a nasal delivery and/or an intramuscular injection. This is hopeful news as biotechnology company CSL started manufacturing the vaccine candidate in Victoria on 9 November 2020. Phase III trials are conducted in large populations in current disease outbreak sites where the virus is in high circulation. While it's important to remember these are provisional results that haven't been peer reviewed, these interim results bring us another step closer to defeating the novel coronavirus and seeing a safe and efficacious vaccine delivered in Australia and around the world. Read more about Oxford University’s interim trial news. |
URL | 查看原文 |
来源平台 | Commonwealth Scientific and Industrial Research Organisation |
文献类型 | 新闻 |
条目标识符 | http://119.78.100.173/C666/handle/2XK7JSWQ/304761 |
专题 | 地球科学 |
推荐引用方式 GB/T 7714 | admin. Expert commentary: Oxford and AstraZeneca vaccine preliminary Phase III data. 2020. |
条目包含的文件 | 条目无相关文件。 |
个性服务 |
推荐该条目 |
保存到收藏夹 |
查看访问统计 |
导出为Endnote文件 |
谷歌学术 |
谷歌学术中相似的文章 |
[admin]的文章 |
百度学术 |
百度学术中相似的文章 |
[admin]的文章 |
必应学术 |
必应学术中相似的文章 |
[admin]的文章 |
相关权益政策 |
暂无数据 |
收藏/分享 |
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。
修改评论